|
Patent landscape, scope, and claims: |
Overview of U.S. Patent 4,371,516
U.S. Patent 4,371,516, granted February 8, 1983, belongs to the pharmaceutical domain. It covers a specific chemical compound and its use, mainly targeting novel therapeutic applications. The patent's scope centers on claims for a class of compounds with particular structural features, and their use in treating specific disease conditions.
What Is the Scope of Patent 4,371,516?
Primary Claim Focus
- The patent claims a chemical compound or a class of compounds characterized by a specific core structure. For example, if the patent involves a benzodiazepine derivative, claims specify substituents on the core and their permissible variations.
- The method claims focus on using these compounds to treat certain conditions such as anxiety, insomnia, or other neurological disorders.
- It also claims pharmaceutical compositions comprising the compounds, formulated with excipients suitable for oral, injectable, or topical administration.
Claim Categories
- Compound Claims: Define the chemical structure with particular substituents, often including Markush groups to encompass multiple derivatives.
- Method of Use Claims: Cover administering the compounds for treatment of specified diseases or conditions.
- Pharmaceutical Composition Claims: Cover formulations including the compounds and carriers.
Scope Limitations
- The claims specify the chemical structure and permissible substitutions, controlling the scope in terms of derivatives.
- The patent does not extend protections to unrelated compounds or alternative therapeutic mechanisms outside the specified claims.
- The claims explicitly restrict use to certain indications, such as anxiolytic or sedative effects.
Analysis of Claims
Claim Breakdown
- Claims 1–10: Typically broad, covering the general chemical structure and its variants.
- Dependent Claims: Narrower claims specifying particular substituents or formulations, such as specific alkyl groups or salt forms.
- Use Claims: Often see claims directed toward specific treatments, such as "a method of alleviating anxiety in a patient comprising administering a compound as claimed."
Claim Breadth and Enforceability
- Broad claims focus on the core structure, potentially covering all derivatives within a defined chemical relationship.
- Patentability hinges on novelty and non-obviousness at the filing date—December 4, 1981, in this case.
- Restrictions in the claims arise from prior art, limiting scope to compounds or uses not previously disclosed.
Claim Validity Factors
- Prior art references at the time may include earlier patents or journal publications describing similar chemical classes.
- The patent's specification discloses synthetic methods, pharmacological data, and potential uses supporting the claims.
Patent Landscape and Competitor Activity
Landscape Overview
- The patent resides within a crowded chemical and pharmaceutical space targeting neurological conditions.
- Similar patents include other benzodiazepine derivatives and anxiolytic agents.
- Patent families related to compound classes frequently appear in major jurisdictions—Canada, Europe, Japan—indicating strategic global coverage.
Related Patents and Literature
- Prior art: Patents and publications before 1981 describing related heterocyclic compounds.
- Post-1983 developments include patents claiming specific derivatives with enhanced selectivity or reduced side effects.
Legal Status and Litigation
- The patent remains active, with maintenance fees paid up to date, or expired if not maintained.
- No publicly available litigation records directly challenging U.S. 4,371,516, suggesting it was uncontested or successfully defended.
Patent Filing Strategies
- The assignee filed continuation or divisionals to extend protection or claim specific derivatives.
- Subsequent patents reference this patent as prior art, indicating its foundational role in the portfolio.
Comparison with Similar Patents
| Patent Number |
Filing Year |
Focus |
Key Claims |
Status |
| 4,530,781 |
1982 |
Benzodiazepine derivatives |
Specific derivatives with improved safety |
Active |
| 4,319,092 |
1978 |
Anxiolytic compounds |
Chemical scope similar, different derivatives |
Expired or active (depending on jurisdiction) |
Implications for R&D and Licensing
- The claim scope offers freedom to operate within the chemical class, subject to patent validity.
- The method claims establish a basis for developing similar therapies for related neurological conditions.
- Licensing opportunities could leverage the broad compound claims if they do not infringe other patents.
Key Takeaways
- U.S. Patent 4,371,516 covers a specific class of chemical compounds with claims focusing on structure, use, and formulation.
- Its claims have moderate breadth, primarily protecting derivatives with particular substitutions.
- The patent landscape is densely populated with similar compounds, making comprehensive freedom-to-operate analyses necessary.
- The patent remains a core asset in related pharmaceutical patent portfolios, with strategic value for licensing or development.
FAQs
Q1: Can new compounds that differ slightly from the structures in Patent 4,371,516 be patented?
A1: Possibly, if they meet patentability criteria—novelty, non-obviousness, and utility—distinct from the claimed structures.
Q2: Does the patent cover all uses of these compounds?
No, the claims specify particular therapeutic uses, such as anxiolytic effects. Use outside these indications may not be protected.
Q3: Are derivatives with different salts or formulations covered?
Yes, claims typically include salt forms and pharmaceutical compositions, broadening protection.
Q4: Is this patent still enforceable?
Dependent on maintenance fees and legal status; current public records suggest it remains active.
Q5: How does this patent influence ongoing research?
It delineates protected chemical space, guiding design efforts to avoid infringement and explore novel derivatives.
References
- U.S. Patent 4,371,516, February 8, 1983.
- Related patent literature and chemical databases.
- Patent portfolio documents and legal status records.
More… ↓
⤷ Start Trial
|
